BJMHR
British Journal of Medical and Health Research
Journal home page: www.bjmhr.com

Epigenetic Pharmacology in Cancer Treatment: Mechanisms and Emerging Therapeutic Strategies

V Lahari Aravinda[1*], P.Sailaja[2], Y.Prapurnachandra[3]
1.Department of Pharmacology, Ratnam Institute of Pharmacy, Pidathapolur(V), Muthukur(M), SPSR Nellore Dt. 524346 A.P. India.
2.Associate Professor, Department of Pharmacology, Ratnam Institute of Pharmacy, Pidathapolur(V), Muthukur(M), SPSR Nellore Dt. 524346 A.P. India.
3.Professor & Principal, Department of Pharmacology, Ratnam Institute of Pharmacy, Pidathapolur(V), Muthukur(M), SPSR Nellore Dt. 524346 A.P. India.

ABSTRACT

Epigenetics plays a crucial role in gene regulation, and its implications in cancer therapy have led to the development of innovative epigenetic drugs. This review explores the fundamental principles of epigenetic modifications and highlights recent advancements in epigenetic pharmacology for cancer treatment and prevention. Current FDA-approved epigenetic therapies primarily include inhibitors targeting DNA methyl transferases (DNMTs) and histone deacetylases (HDACs). However, future therapeutic strategies may involve inhibitors of histone methyltransferases, histone demethylases, and other key epigenetic regulators. Epigenetic drugs exert their effects in two interconnected ways. Firstly, they restore aberrant epigenetic modifications in malignant and premalignant cells, thereby reversing dysregulated gene expression and serving as a foundation for epigenetic therapy. Secondly, these drugs modulate non-histone proteins that regulate crucial cellular processes such as proliferation, migration, and apoptosis. Through these mechanisms, epigenetic drugs induce cancer cell cycle arrest, differentiation, inhibition of tumour angiogenesis, and cell death via apoptosis, autophagy, necrosis, or mitotic catastrophe. This review provides an in-depth analysis of the molecular mechanisms underlying epigenetic drug action and their clinical applications. With ongoing research, novel epigenetic therapies hold promise for more precise and effective cancer treatments, paving the way for personalized medicine in oncology.

Keywords: Epigenetics, DNA methylation, histone acetylation, gene regulation, cancer therapy, epigenetic inhibitors, targeted therapy.

*Corresponding Author Email: sailapharma87@gmail.com
Received 12 February 2025, Accepted 19 March 2025

Please cite this article as: Aravinda VL *et al*., Epigenetic Pharmacology in Cancer Treatment: Mechanisms and Emerging Therapeutic Strategies. British Journal of Medical and Health Research 2025.

INTRODUCTION

The development and assessment of analgesics have long focused on designing high-affinity, highly selective mu-opioid peptide (MOP) receptor agonists, which remain the foundation of pain management. Clinically used opioids such as morphine and fentanyl provide effective analgesia, but their use is limited by adverse effects such as respiratory depression, tolerance, and addiction (1). Pharmacokinetic advancements, such as remifentanil, were developed to address these issues by enabling rapid metabolism, yet challenges related to opioid dependency and overdose persist (2).

The opioid receptor family consists of delta-opioid peptide (DOP), kappa-opioid peptide (KOP), and nociception/orphanin FQ (NOP) receptors, all of which contribute to pain modulation and opioid effects (3). Functional interactions among these receptors influence both therapeutic outcomes and side-effect profiles, making them a significant focus for designing safer and more effective analgesics (4).

The Dual Crisis of Opioid Use

Opioid misuse has escalated into a public health epidemic, particularly in the United States. Between 2000 and 2014, opioid-related overdose deaths doubled, involving both prescription opioids and illicit heroin (5). While strict opioid prescribing policies have been introduced, their impact on opioid abuse remains uncertain (6). This epidemic is often described as two interrelated crises:

1. The increasing misuse and addiction to opioids, driven by widespread prescribing and illicit drug use (7).
2. The challenge of managing chronic pain, where restrictions on opioid access have left many patients suffering inadequate pain relief (8).

Classification and Mechanisms of Opioids

Opioids are categorized based on their synthesis into natural alkaloids (e.g., morphine, codeine), semisynthetic (e.g., oxycodone, hydromorphone), and synthetic compounds (e.g., fentanyl, methadone) (9). They can also be classified by their pharmacological action at opioid receptors, where they act as agonists, antagonists, or partial agonists (10).

MOP receptor agonists function through G-protein-coupled receptor (GPCR) activation, leading to cellular hyperpolarization and inhibition of pain signaling (11). Despite their potency in pain relief, their high abuse potential has driven the need for alternative analgesics with reduced side effects (12).

Natural Opioids and Their Derivatives

Among naturally occurring opioids, morphine remains the most widely used analgesic, derived from the opium poppy (Papaver somniferum) (13). Other notable alkaloids isolated from the plant include:

- Codeine, commonly prescribed for mild to moderate pain relief (14).
- Papaverine, a smooth muscle relaxant with minimal analgesic properties (15).
- Thebaine, a precursor for semisynthetic opioids like oxycodone and naloxone (16).

Despite their medical benefits, opioid dependence, withdrawal symptoms, and overdose risks remain significant concerns, necessitating ongoing research into safer analgesic alternatives (17).

Epigenetic Mechanisms in Cancer

Epigenetic modifications play a crucial role in cancer development by regulating gene expression without altering the underlying DNA sequence. These changes can drive tumourigenesis through DNA methylation, histone modifications, chromatin remodeling, and non-coding RNA (ncRNA) interactions. Understanding these mechanisms is essential for developing targeted epigenetic therapies for cancer treatment.

Key Epigenetic Mechanisms in Cancer

1. DNA Methylation

One of the most well-studied epigenetic modifications in cancer is abnormal DNA methylation patterns. In many malignancies, hypermethylation of tumour suppressor genes leads to their silencing, preventing their ability to regulate cell division and apoptosis. Conversely, hypomethylation of oncogenes can lead to their overexpression, driving uncontrolled cell proliferation. These alterations contribute significantly to genomic instability and tumour progression.

2. Histone Modifications

Histones, the proteins around which DNA is wrapped, undergo various post-translational modifications that affect chromatin structure and gene expression. Acetylation, methylation, phosphorylation, and ubiquitination can either promote or suppress transcription, depending on the specific modification and the site of action. Aberrant histone modifications in cancer cells can create an environment that supports tumour growth, survival, and metastasis.

3. Chromatin Remodelling

The structure of chromatin plays a key role in regulating access to genetic information. Chromatin remodelling complexes actively modify nucleosome positioning, either making DNA more accessible for transcription or compacting it to suppress gene expression. Dysfunction in chromatin remodelling proteins can lead to inappropriate activation or silencing of genes involved in cancer progression, contributing to tumour development.

Epigenetic and Genetic Contributions to Cancer

Cancer arises from a complex interplay between genetic mutations and epigenetic alterations. While genetic mutations directly change the DNA sequence, epigenetic changes influence which genes are expressed at any given time. These modifications often occur before genetic mutations and can increase susceptibility to oncogenic transformation. Additionally, epigenetic changes enhance tumour heterogeneity, making cancer more adaptable and resistant to therapy.

Basic Concepts of Epigenetic Gene Regulation

The regulation of gene expression through epigenetic mechanisms primarily involves three interconnected processes:

1. DNA Methylation

- Mediated by DNA methyltransferases (DNMTs), which add methyl groups to cytosine residues in CpG sites.
- DNMT1 maintains methylation patterns during DNA replication, while DNMT3A and DNMT3B introduce new methylation marks.
- Controls genomic stability, imprinting, and transcriptional regulation.

2. Histone Modifications

- Regulated by histone acetyltransferases (HATs) and histone deacetylases (HDACs) for acetylation.
- Histone methyltransferases (HMTs) and histone demethylases (HDMs) modify methylation states at lysine or arginine residues.
- Alter chromatin accessibility, influencing gene activation or repression.

3. Non-Coding RNAs (ncRNAs)

- MicroRNAs (miRNAs) and long non-coding RNAs (lncRNAs) regulate post-transcriptional gene expression.
- Act by binding to messenger RNA (mRNA) to prevent translation or promote degradation.
- Play a key role in cancer by controlling genes involved in cell cycle regulation, apoptosis, and metastasis.

Additionally, emerging evidence suggests that replication timing and subnuclear positioning of chromatin domains are crucial for epigenetic gene regulation in specific contexts.

Approved Epigenetic Drugs in Cancer Therapy

Several epigenetic drugs have been approved by the U.S. Food and Drug Administration (FDA) for treating cancer, particularly hematologic malignancies. These drugs target key epigenetic enzymes to reverse aberrant gene expression patterns in cancer cells.

1. DNMT Inhibitors

- Azacitidine (Vidaza®) – Approved in 2004 for treating myelodysplastic syndromes (MDS).
- Decitabine (Dacogen®) – Another DNMT inhibitor used for MDS and acute myeloid leukaemia (AML).

These agents work by inhibiting DNA methylation, leading to reactivation of silenced tumour suppressor genes.

2. HDAC Inhibitors

- Vorinostat (Zolinza®) – Approved for treating cutaneous T-cell lymphoma (CTCL).
- Valproic Acid (VPA) – Though primarily used for epilepsy and mood disorders, it also exhibits HDAC inhibitory properties and is being studied for its anti-cancer effects.

3. Other Emerging Epigenetic Drugs

- Arsenic Trioxide (Trisenox®) – Initially used for acute promyelocytic leukaemia, later found to inhibit DNMTs.
- Researchers are actively investigating histone methyltransferase (HMT) and histone demethylase (HDM) inhibitors for greater specificity in cancer treatment.
- Epigenetic drugs have also shown promise in treating non-malignant diseases, including HIV, chromosomal instability syndromes, and neurodevelopmental disorders.

Intratumour Epigenetic Alterations

Cancer progression is influenced by genomic and epigenomic changes, leading to tumour heterogeneity. Two main models describe tumour evolution:

1. The Cancer Stem Cell (CSC) Model

- Proposes that a small population of cancer stem cells initiates and sustains tumour growth.
- These cells exhibit self-renewal properties and contribute to drug resistance.

2. The Clonal Evolution Model

- Suggests that cancer cells acquire mutations progressively, leading to a diverse population of tumour cells.
- Sub clonal variations arise, influencing treatment response and disease progression.

Epigenetic alterations can impact both models by influencing genetic mutations, sub clonal diversity, and treatment resistance. Targeting epigenetic modifications could therefore enhance therapy effectiveness by addressing tumour plasticity and heterogeneity.

Combination Therapies Involving Epigenetic Drugs

Epigenetic drugs are increasingly being explored in combination with other therapies to overcome drug resistance and improve cancer treatment outcomes.

1. Epigenetic Therapy & Chemotherapy

- HDAC and DNMT inhibitors can sensitize cancer cells to chemotherapy by restoring tumour suppressor gene function.
- Example: Combining DNMT inhibitors with cytotoxic agents improves responses in leukaemia and solid tumours.

2. Epigenetic Therapy & Immunotherapy

- Epigenetic drugs can reactivate silenced immune-related genes, improving the immune system's ability to detect and attack cancer cells.
- Example: HDAC inhibitors enhance the effectiveness of immune checkpoint inhibitors (e.g., PD-1/PD-L1 blockade).

3. Epigenetic Therapy & Targeted Therapy

- Combining epigenetic drugs with tyrosine kinase inhibitors or hormonal therapies can overcome drug resistance.
- Example: HDAC inhibitors combined with EGFR inhibitors improve outcomes in lung cancer.

Epigenetic Modulation in Cancer Therapy

HMT and HDM Inhibitors

Histone Methyltransferase (HMT) Inhibitors

The first inhibitor targeting a lysine-specific HMT was reported by Greiner et al. in 2005. This compound, chaetocin, a fungal metabolite, specifically inhibits the methyltransferase Su(var)3-9. Since then, chemical library screenings have led to the discovery of other HMT inhibitors. One such compound, BIX-01294, selectively inhibits G9a HMT, which is responsible for the methylation of histone 3 at lysine 9 (H3K9me2). This inhibitor enables transient modulation of H3K9me2 marks in mammalian chromatin, making it a valuable tool in epigenetic research and potential cancer therapy.

Histone Demethylase (HDM) Inhibitors

Several inhibitors have been identified for histone demethylases (HDMs), particularly in the context of cancer therapy. Compounds such as trans-2-phenylcyclopropylamine and pargyline have shown inhibitory effects on lysine-specific demethylase 1 (LSD1). However, their specificity and potency remain limited, necessitating further research to develop more selective and effective HDM inhibitors.

Combination Therapy with Epigenetic Drugs for Cancer Treatment

Enhancing Efficacy Through Combination Approaches

While epigenetic drugs alone have shown limited anti-tumour activity, their combination with other therapeutic modalities has demonstrated improved outcomes in both leukaemia and solid tumours. These synergistic approaches help enhance the effectiveness of treatment, offering potential breakthroughs in cancer management.

Epigenetic Modulation of Drug Resistance

Genetic Variability and Drug Metabolism

Variability in drug response is often attributed to differences in drug-metabolizing enzymes, such as cytochrome P450 (CYP450) and glucuronyl transferase. These enzymes are encoded by polymorphic genes that influence drug metabolism. For instance, genetic variations in CYP2D6 and CYP2C19, which impact the metabolism of approximately 25% of prescribed drugs, can be detected using microarray technology.

Genetic and Epigenetic Influence on Drug Sensitivity

Drug receptors, such as **receptor tyrosine kinases (RTKs)**, also undergo genetic mutations that affect treatment efficacy. For example:

- Overexpression of ERBB2 (HER2) in breast cancer is treated with trastuzumab.
- The BCR/ABL fusion protein in leukaemia is highly sensitive to imatinib.
- EGFR mutations are linked to responsiveness to gefitinib.

Understanding these genetic variations and epigenetic modifications is crucial for advancing personalized cancer treatments.

Epigenetic Agents in Combination with Chemotherapy

Improved Therapeutic Outcomes

Studies have shown that histone deacetylase inhibitors (HDACi) demonstrate enhanced anti-tumour effects when combined with chemotherapy. These combinations have been effective against multiple cancer types, including multiple myeloma and solid tumours. Key examples include:

- Proteasome inhibitor bortezomib combined with vorinostat, MS-275, or valproic acid (VPA) induces apoptosis in cancer cells by causing oxidative stress and disrupting protein degradation pathways.
- HDACi combined with tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) enhances cancer cell apoptosis without harming normal cells.
- Vorinostat combined with the DR5-specific monoclonal antibody (MD5-1) promotes tumour regression in preclinical models.

Epigenetic Drugs as Chemo preventive Agents

Dietary compounds with epigenetic-modulating properties have shown promise in cancer prevention. Cruciferous vegetables like broccoli, Brussels sprouts, and cabbage contain sulforaphane (SFN), a natural compound with anti-cancer properties. SFN modulates epigenetic marks, making it a potential agent for cancer chemoprevention.

Epigenetic Therapy and Immunotherapy

Restoring Immune Recognition

Cancer cells often evade immune detection by down regulating genes involved in antigen processing and presentation. Many of these genes are epigenetically silenced, but epigenetic drugs such as HDACi can reverse this process, enhancing immune system recognition.

Targeting Cancer-Germline (CG) Antigens

CG antigens are selectively expressed in cancer cells and can be further up regulated by DNMTi and HDACi, making them ideal targets for cancer immunotherapy. The restoration of immune function via epigenetic drugs enhances the efficacy of immunotherapeutic approaches.

Advancing Epigenetic-Based Therapeutic Strategies

Targeting Epigenetic Enzymes

Several epigenetic enzymes, including DNA methyltransferases (DNMTs), histone deacetylases (HDACs), and histone methyltransferases (HMTs), are under investigation for cancer treatment. Drugs targeting these enzymes aim to reprogram the epigenome of cancer cells, potentially restoring normal gene expression and improving responsiveness to chemotherapy.

Epigenetic Reprogramming

By reversing cancer-associated epigenetic alterations, epigenetic reprogramming seeks to reset the epigenome to a non-malignant state. This approach could enhance the efficacy of existing therapies and prevent cancer progression.

Challenges and Future Directions

1. Tumour Heterogeneity

Different regions within the same tumour often exhibit distinct epigenetic profiles, complicating the development of universal therapies. Addressing tumour heterogeneity remains a major challenge in epigenetic research.

2. Off-Target Effects

Epigenetic drugs can inadvertently affect non-cancerous genes, leading to unintended side effects. Research is ongoing to develop more selective agents to minimize toxicity.

3. Personalized Medicine

The diversity of epigenetic alterations across cancer types underscores the need for personalized treatment strategies. Advances in epigenomic profiling could enable tailored therapies based on the unique epigenetic landscape of a patient's tumour.

4. Resistance to Epigenetic Therapies

Just like traditional chemotherapy, cancer cells can develop resistance to epigenetic drugs. Understanding the mechanisms of resistance is critical for designing next-generation epigenetic therapies.

Nutrition and the Epigenome

One of the most significant connections between diet and the epigenome is found in one-carbon metabolism, where nutrients such as methionine and folate play a crucial role in synthesizing the methyl donor S-adenosylmethionine (SAM). Any imbalance in the intake of these nutrients can influence methylation reactions, altering DNA methylation patterns and histone methylation marks, ultimately affecting chromatin structure and gene expression.

Recent genome-wide studies on DNA methylation profiles in various cancers suggest that hypermethylation leading to gene silencing is only one aspect of the broader epigenetic landscape. Some genes act as drivers of carcinogenesis and metastasis, and using SAM to methylate and silence these genes presents a targeted approach to inhibiting metastasis. Additionally, SAM has been explored as a potential treatment for Alzheimer's disease, where it restores the epigenetic regulation of the β-secretase gene through hypermethylation, leading to a reduction in amyloid plaque formation.

The Role of Small and Large RNAs

Approximately 60% of the human genome is transcribed into RNA, but only around 3% is translated into proteins. The remaining portion consists of non-coding RNAs (ncRNAs), which do not directly code for proteins but play significant regulatory roles. Some ncRNAs, such as ribosomal RNA (rRNA) and transfer RNA (tRNA), are involved in protein synthesis, while others, like microRNAs (miRNAs), regulate post-transcriptional gene expression.

MiRNAs are particularly significant in controlling gene function by dampening mRNA activity. They influence various biological processes, including development, homeostasis, metabolism, immunity, apoptosis, and cell proliferation. These small RNAs serve as "fine-tuners" of cellular processes in healthy cells and have been implicated in disease conditions. Because miRNAs can regulate multiple genes within entire pathways, they present potential targets for pharmacological interventions.

There are nearly 3,000 distinct miRNA species, and clinical trials are currently exploring their use as therapeutic agents for conditions such as primary liver cancer, glioblastoma, and non-small cell lung cancer (NSCLC). Long ncRNAs, which are over 200 base pairs long,

remain less understood compared to miRNAs but are believed to play critical roles in gene regulation.

The Advancement of Epigenetic Drugs

The approval of the first generation of epigenetic drugs has solidified epigenetic modulation as a viable strategy for cancer treatment. However, this field is still in its early stages, with significant improvements expected in the coming years. Currently, around 30 epigenetic drugs are in development by multiple biopharmaceutical companies, with most of them being designed for cancer therapy.

The next generation of epigenetic drugs is likely to demonstrate greater specificity, benefiting from a deeper understanding of epigenetic mechanisms in cancer. Future therapies could include inhibitors targeting additional epigenetic enzymes. Research has shown that certain endogenous molecules regulate Class I histone deacetylases (HDACs) in vivo, further expanding the potential of epigenetic-based treatments.

In the coming decades, epigenetic drugs are expected to become a standard class of pharmaceuticals for not only leukaemia but also solid tumours. Some of these drugs may also be utilized for cancer prevention, offering a proactive approach to managing disease.

CONCLUSION

Epigenetics presents a ground breaking opportunity to transform cancer treatment by addressing the underlying molecular mechanisms of the disease. By targeting epigenetic modifications, therapies can become more effective and personalized, ultimately leading to improved patient outcomes. Understanding the role of epigenetics in cancer development, progression, and drug response enables researchers to devise novel therapeutic strategies that enhance drug efficacy, overcome resistance, and potentially reverse some cancer-related abnormalities. However, challenges such as tumour heterogeneity and unintended off-target effects must be addressed to optimize these treatments. Continued research into the epigenome and its relationship with pharmacology will be vital for realizing the full potential of epigenetic-based therapies. Personalized medicine, driven by an individual's genomic profile, is emerging as a powerful approach in managing diseases. While several epigenetic drugs have already received FDA approval, further advancements are needed to refine their application and effectiveness. The future of cancer treatment lies in combining genetic insights with epigenetic interventions, ensuring that therapies are tailored to each patient's unique biological makeup.

REFERENCES

1. Brown, M. T., et al. (2019). Role of opioid receptors in pain modulation. *Pain Research and Management*, 24(3), 145-157.

2. CDC (2017). Opioid overdose: Understanding the epidemic. *Centers for Disease Control and Prevention Report*.
3. Gomes, T., et al. (2021). Impact of opioid receptor interactions on analgesia. *Journal of Pain and Symptom Management*, 62(4), 655-671.
4. Jones, C. M., & Becker, W. C. (2020). Trends in opioid prescribing and related deaths. *JAMA Internal Medicine*, 180(5), 705-715.
5. Kruegel, A. C., & Grundmann, O. (2018). The pharmacology of natural and synthetic opioids. *Annual Review of Pharmacology and Toxicology*, 58, 253-275.
6. Manchikanti, L., et al. (2018). The evolving opioid epidemic. *Pain Physician*, 21(2), 111-134.
7. Dowell, D., et al. (2019). Clinical guidelines for opioid prescribing. *New England Journal of Medicine*, 380(1), 36-47.
8. Pergolizzi, J. V., et al. (2020). Strategies for safer opioid use. *Expert Opinion on Pharmacotherapy*, 21(5), 573-589.
9. Rosenblum, A., et al. (2017). Opioid use in pain management: Risks and benefits. *Clinical Journal of Pain*, 33(3), 409-419.
10. Schmid, C. L., et al. (2017). Pharmacology of opioid derivatives. *Molecular Pharmacology*, 91(2), 145-155.
11. Smith, H. S., et al. (2018). The mechanism of opioid-induced analgesia and tolerance. *Pain Medicine*, 19(3), 568-584.
12. Stein, C. (2016). Opioids in pain therapy. *The Lancet*, 387(10027), 2570-2580.
13. Volkow, N. D., & McLellan, A. T. (2016). The role of opioids in pain and addiction. *New England Journal of Medicine*, 374(13), 1253-1263.
14. Williams, J. T., et al. (2018). The cellular mechanisms of opioid analgesia. *Nature Reviews Neuroscience*, 19(7), 381-397.
15. Yekkirala, A. S., et al. (2017). Beyond opioid analgesics: Novel approaches for pain management. *Nature Reviews Drug Discovery*, 16(10), 585-600.
16. Becker, W. C., et al. (2020). Alternative treatments for chronic pain. *Journal of Pain Research*, 13, 1045-1058.
17. Bushnell, M. C., et al. (2019). Gender differences in pain perception and opioid response. *Pain*, 160(1), 77-89.
18. Che, T., et al. (2018). Opioid receptor signaling complexity. *Cell*, 172(1-2), 55-67.
19. Comer, S. D., et al. (2019). Opioid-induced respiratory depression: Mechanisms and reversal strategies. *Journal of Pharmacology and Experimental Therapeutics*, 368(3), 356-367.

20. Kosten, T. R., & George, T. P. (2018). The neurobiology of opioid addiction. *American Journal of Psychiatry*, 175(5), 353-365.
21. Pasternak, G. W., & Pan, Y. X. (2018). Opioid receptors: Structure and function. *Annual Review of Pharmacology and Toxicology*, 58, 353-380.
22. Taylor, B. K., & Westlund, K. N. (2017). The role of opioids in chronic pain management. *Pain Medicine*, 18(9), 1801-1810.
23. Zhao, Y., et al. (2019). Opioid metabolism and drug interactions. *Clinical Pharmacokinetics*, 58(5), 669-680.
24. Zöllner, C., & Stein, C. (2017). Opioid analgesia: Mechanisms and opioid tolerance. *Current Opinion in Pharmacology*, 37, 27-33.
25. Zuber, J., et al. (2021). Advances in opioid receptor pharmacology. *Trends in Pharmacological Sciences*, 42(3), 200-213.
26. Baylin, S. B., et al. (2016). The cancer epigenome: A target for treatment and personalized medicine. Nature Reviews Cancer, 16(6), 303-310.
27. Berdasco, M., & Esteller, M. (2019). Clinical epigenetics: Seizing opportunities for translation. Nature Reviews Genetics, 20(2), 109-127.
28. Dawson, M. A., et al. (2017). Epigenetic therapies: The next frontier in cancer treatment. Science, 355(6330), 1147-1152.
29. Feinberg, A. P., & Tycko, B. (2020). The history of cancer epigenetics. Nature Reviews Cancer, 20(6), 359-368.
30. Flavahan, W. A., et al. (2017). Epigenetic plasticity and the hallmarks of cancer. Science, 357(6348), eaal2380.
31. Jones, P. A., & Baylin, S. B. (2018). The epigenomics of cancer. Cell, 173(6), 1323-1337.
32. Kelly, T. K., et al. (2018). Epigenetic modulation of cancer chemotherapy resistance. Annual Review of Pharmacology and Toxicology, 58, 432-457.
33. Knutson, S. K., et al. (2019). Epigenetic therapies in oncology: Targeting the chromatin regulators. Nature Reviews Drug Discovery, 18(9), 673-693.
34. Kulis, M., & Esteller, M. (2019). DNA methylation and cancer. Advances in Genetics, 104, 27-56.
35. Li, X., et al. (2018). Epigenetic reprogramming in cancer therapy: Mechanisms and clinical efficacy. Oncogene, 37(1), 1-15.
36. Loo, Y. D., & Gokul, G. (2020). HDAC inhibitors: Beyond epigenetics in cancer therapy. Drug Discovery Today, 25(4), 843-855.

37. Deepthi V, Rao PK, Vasanth PM (2014). Evaluation of therapeutic response of methotrexate and calcipotriol combination compared with methotrexate alone in plaque psoriasis. *Our Dermatol Online*, 5(2), 118-123.
38. Ramya P, Vasanth P M, Prasad P V, Babu S V (2019). Qualitative phytochemical screening tests of Alpinia galanga L. *World Journal of Pharmaceutical Research*, 8(5), 1064-1077.
39. Prasanthi, R. M., Vasanth, P. M., & Ramesh, T. (2013). Assays for oxidative stress and antioxidant status. *Research Journal of Pharmaceutical, Biological and Chemical Sciences*, 4(1), 846-856.
40. Mazzone, R., et al. (2019). The role of DNA methylation in aging and cancer. Journal of Experimental & Clinical Cancer Research, 38(1), 1-18.
41. Ndlovu, M. N., et al. (2020). The role of histone modifications in the development of cancer drug resistance. Trends in Pharmacological Sciences, 41(8), 611-627.
42. Sharma, S., et al. (2019). The role of microRNAs in cancer epigenetics. Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, 1862(3), 371-385.
43. Verdone, L., et al. (2020). Epigenetic therapy of cancer: An update and future perspectives. Oncology Reports, 44(5), 2212-2225.
44. Yoo, C. B., & Jones, P. A. (2018). Epigenetic therapy—Targeting DNA methylation and histone modifications. Nature Reviews Drug Discovery, 17(12), 813-833.